4 results about "Trimethylbromosilane" patented technology

The invention discloses a synthesis method of a cyclic oligomer carbazole phosphate hole transport material. According to the material, carbazole phosphoric acid units are directionally connected into a cyclic oligomeric structure through intramolecular cyclization design, cyclic oligomer carbazole phosphoric acid with different hydrolysis degrees is obtained by adjusting the concentration of trimethylbromosilane in hydrolysis reaction, and the charge transfer capacity and the interface passivation effect of the material are remarkably improved. Compared with the traditional self-assembled monomolecular layer (SAM) type carbazole phosphoric acid micromolecule (such as PACz), the Cyclic-PACz has better long-term operation stability and large-area coating compatibility.

This invention discloses the preparation of a nitrogen-containing phosphate resin monomer and its application as an indicator of iron ions. The structure of the compound is shown in the figure below. Using a phosphorus-containing heptanobromoborone compound from the paper "Preparation of a Phosphorus-Containing Heptanobromoborone Compound and Its Application in Fluorescent Ink" as a raw material, the compound undergoes a hydrolysis reaction under the action of trimethylbromosilane to generate a nitrogen-containing phosphate resin monomer. The synthetic route is simple, the post-processing is convenient, and the product yield is high. This compound exhibits high fluorescence quantum yield in both organic and aqueous phases. Ultimately, this compound is used for the indication of iron ions in aqueous phases. 3+ It exhibits selective detection with high sensitivity.

The invention provides a hole transport material containing a polyphosphoric acid anchoring group, a synthesis method and application thereof, and the synthesis method of the hole transport material containing the alkyl polyphosphoric acid anchoring group comprises the following steps: S1, taking a benzodithiophene derivative with an alkyl chain as an initial compound; deprotonating and reacting with dibromoalkane to obtain a brominated alkyl compound; s2, reacting the brominated alkyl compound with triethyl phosphite to obtain a diethyl phosphonate compound; s3, hydrolyzing the diethyl phosphonate compound through trimethylbromosilane to obtain a hole transport material containing a phosphoric acid anchoring group; wherein the alkyl chain is C1-20 alkyl, and the benzodithiophene derivative has a plurality of modifiable sites so as to introduce single-side or double-side phosphate groups. The invention solves the problem that the core conjugate unit of the current self-assembled hole transport material has few modifiable sites and limits the optimization space of the material.

The invention discloses a preparation method of a targeted drug polypeptide for glioma treatment, which comprises the following steps: 1) preparing a small molecule inhibitor couple TGN020-5ca of AQP4, and the structural formula of the TGN020-5ca is as follows: 2) sequentially adding different amino acids into a solid-phase synthesis tube to obtain a polypeptide, and reacting the polypeptide with trimethylbromosilane and methanol to obtain a methyl esterified polypeptide; and 3) preparing the polypeptide-TGN020: firstly adding N-hydroxysuccinimide and N, N '-diisopropyl carbodiimide, activating carboxyl on the TGN020-5ca at the activation temperature of 37-60 DEG C for 6-8 hours, then adding polypeptide or methyl esterified polypeptide and N, N-diisopropyl ethylamine, and reacting at the temperature of 25-37 DEG C for 1-2 hours, the molar ratio of the TGN020-5ca to the polypeptide or methyl esterified polypeptide being 1.2: 1-1.5: 1. The polypeptide TGN020 is targeted and accumulated on a glioma cell membrane, can inhibit the rate of water molecules entering and exiting from glioma cells in a long-acting manner, effectively inhibits the malignant proliferation rate of glioma, has the capabilities of targeted enrichment and long-acting AQP4 inhibition, and has excellent glioma cell killing capability.